Clinical trials: Pemphigus Disease
Pemphigus Vulgaris
Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.
To assess the therapeutic efficacy of low level laser therapy on oral pemphigus vulgaris patients.
- Trial name
- NCT06971172
- Testing
- Low energy diode Laser, Medication
- Volunteers
- 22 people
- Sponsor
- Cairo University
Gingival Diseases, Gingivitis
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Chronic erosive gingivitis is a syndrome (CEGS) that combines severe gingival inflammation and gingival erosion. The term "desquamative gingivitis" is often used in the literature to define chronic erosive gingivitis.
- Conditions
- Gingival Diseases, Gingivitis, Autoimmune Diseases, Oral Lichen Planus
- Trial name
- NCT04293718
- Testing
- papillary gum biopsies
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pemphigus, Dermatological Disease
Identification of Vulnerability Factors in the Course of Pemphigus Patients
The bullous pemphigoid treatment is based on corticosteroids continued for several years. Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at…
- Trial name
- SHS-Pemphigus (NCT02237313)
- Testing
- psychological support and therapeutic education program
- Where
- 9 sites in France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Rouen
Pemphigus, Steroid-resistant Pemphigus
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus
- Trial name
- NCT06696716
- Testing
- ONO-4059
- Where
- 25 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a…
- Conditions
- Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum, Erosive Pustular Dermatosis of the Scalp, Sweet's Syndrome
- Trial name
- NEUTROGENE (NCT01952275)
- Testing
- Collection of biological samples
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- University of Zurich
Pemphigus Disease, Rituximab (RTx)
A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center
Pemphigus is a critical autoimmune skin condition mediated by pathogenic autoantibodies mainly against desmoglein (Dsg)1 and Dsg3, and is traditionally managed with systemic corticosteroids and immunosuppressants.The…
- Conditions
- Pemphigus Disease, Rituximab (RTx), Intravenous Immunoglobulin
- Trial name
- NCT06949241
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Ruijin Hospital
Pemphigus
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who…
- Trial name
- NCT02613910
- Testing
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Pemphigus Disease, Rituximab (RTx)
Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients
Investigating the clinical efficacy of different doses of rituximab in patients with pemphigus
- Trial name
- NCT07457944
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Ruijin Hospital
Pemphigus Vulgaris
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
Description: Pemphigus vulgaris is an autoimmune, chronic and recurrent blistering disease with unknown etiology that affects mucosa and skin of patients with significant morbidity and mortality.
- Trial name
- NCT00626678
- Testing
- Azathioprine, Prednisone
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Tehran University of Medical Sciences
Pemphigus
Validation of 5-Point Investigator Global Assessments for Pemphigus
This study aims to explore the reliability and validity of newly developed Investigator Global Assessments (IGAs) in scoring the severity of pemphigus.
- Trial name
- NCT05534776
- Testing
- Investigator Global Assessments (IGAs)
- Where
- 7 sites in Australia, Bulgaria and 5 more
- Volunteers
- 40 people
- Sponsor
- Premier Specialists, Australia
Pemphigus Vulgaris
CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris
This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with…
- Trial name
- RESET-PV-CART (NCT07681388)
- Testing
- Autologous CD19 CAR-T cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Jinbo Chen
Pemphigus
A Single-center Study of CM313 in Patients With Pemphigus
A prospective, single-center, single-arm clinical study aimed to explore the efficacy and safety of the anti-CD38 monoclonal antibody CM313 combined with low-dose glucocorticoids in patients with pemphigus.
- Trial name
- NCT06904040
- Testing
- CM313 injection, glucocorticoids
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Provincial People's Hospital
Pemphigus Vulgaris
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.Abatacept is a biologic drug that belongs to the class of T-cell…
- Trial name
- NCT05303272
- Testing
- Abatacept Prefilled Syringe, Mycophenolate Mofetil 500Mg Tab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tongji Hospital
Oral Lichen Planus, Mucous Membrane Pemphigoid
Dexamethasone Solution and Dexamethasone in Mucolox™
Topical steroid therapy is considered the first line of treatment for Oral Inflammatory Ulcerative Diseases with current treatment regimens requiring multiple application or rinses daily.
- Conditions
- Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
- Trial name
- NCT04540133
- Testing
- dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pemphigus Vulgaris
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
The purpose of this study is to determine if the use of PI-0824 in patients with Pemphigus vulgaris is safe.
- Trial name
- NCT00063752
- Testing
- PI-0824
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Peptimmune
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This was a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who…
- Trial name
- ADDRESS+ (NCT04598477)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 183 people
- Sponsor
- argenx
Pemphigus, Auto-immune Thrombocytopenic Purpura
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.
- Conditions
- Pemphigus, Auto-immune Thrombocytopenic Purpura, Hemolytic Auto-immune Anaemia, Cold Agglutinin Disease
- Trial name
- RITAI (NCT00960713)
- Testing
- Rituximab (MABTHERA® or RITUXAN®).
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Pemphigus, Pemphigus Vulgaris
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
- Conditions
- Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus
- Trial name
- NCT03075904
- Testing
- ALXN1830
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.